Clinical Trial Update: An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease [Phase 1]

View source ↗

Summary

An open-label Phase 1 maintenance study of Replagal (agalsidase alfa) for Fabry disease has been completed, according to the trial record.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Replagal (agalsidase alfa)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Fabry Disease | Phase 1 | Status: COMPLETED